Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation neuroplasticity inducing medicines to treat underserved mood and anxiety disorders.

www.lophora.com

Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate LPH-5 through funding granted by the BII (Novo Nordisk Foundation), public funds and experienced biotech investors. Lophora will initiate first-in-human trials by 2024.

Efficacy of LPH-5 has been extensively characterized in vivo and has successfully completed GLP-Tox with expected CTA submission by Q2 2024.

Lophora

Org chart

Teams

Offices